Reviva Pharmaceuticals Holdings, Inc. — Cyborg Score 4/10

Strategic Profile

Reviva filed a composition-of-matter provisional patent application for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046. Patient enrollment in the RECOVER-2 Phase 3 trial is expected in Q3 2026, with FDA feedback on the new brilaroxazine form expected in mid-2026.

Cyborg Score Rationale

Reviva's stock was delisted from NASDAQ on May 14, 2026 and moved to OTCQB. The company reported a net loss of $19.9M for 2025 with only $14.4M cash at year-end. Post-March 2026 offering, management believes cash covers operations into early 2027 but will require additional fundraising.

Top Insights

• FDA recommended a second Phase 3 clinical trial for brilaroxazine to generate additional efficacy data and expand the safety dataset.
• New brilaroxazine formulation targets patent extension and commercial exclusivity, with FDA feedback expected mid-2026.
• March 2026 public offering raised $10.0 million gross through sale of 6,666,667 common shares with warrants.
• Operating expenses fell 50% year-over-year in Q1 2026, with R&D down 65% to focus capital on RECOVER-2 trial initiation.

Named Competitors

• Abilify (aripiprazole) — Widely-used atypical antipsychotic for schizophrenia
• Risperdal (risperidone) — Established atypical antipsychotic
• Latuda (lurasidone) — Modern antipsychotic with favorable metabolic profile

Recent Developments

• (May 2026) Stock delisted from NASDAQ and moved to OTCQB Venture Market
• (May 2026) Reported Q1 2026 financial results with reduced operating expenses and disclosed FDA feedback timeline
• (March 2026) Completed $10 million public offering to fund RECOVER-2 Phase 3 trial
• (December 2025) FDA recommended second Phase 3 trial for brilaroxazine in schizophrenia

Open the full interactive Reviva Pharmaceuticals Holdings, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.